BMEA (Biomea Fusion) Short Interest


BMEA Biomea Fusion Inc BMEA
31 GF Score
Price $1.28
! 1 Warning Sign
View Full Analysis

What is Biomea Fusion Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BMEA vs VRCA, PMN, SEER: Short Interest Comparison

For the Biotechnology subindustry, Biomea Fusion's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomea Fusion Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's Short Interest distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's Short Interest falls into.


BMEA
31GF Score
Biomea Fusion Inc BMEA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomea Fusion Business Description

Address 1599 Industrial Road, San Carlos, CA, USA, 94070
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
31GF Score

Get the complete analysis for BMEA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.28
Price